Source: https://www.federalregister.gov/documents/2013/03/25/2013-06748/new-animal-drug-approvals-change-of-sponsor-change-of-sponsors-drug-labeler-code-gonadorelin-acetate
Timestamp: 2017-08-24 00:32:50
Document Index: 280508263

Matched Legal Cases: ['arts 522', 'arts 510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009524', '§\u2009529', '§\u2009529']

Federal Register :: New Animal Drug Approvals; Change of Sponsor; Change of Sponsor's Drug Labeler Code; Gonadorelin Acetate; Isoflurane; Praziquantel; Propofol; Sevoflurane; Triamcinolone Acetonide
A Rule by the Food and Drug Administration on 03/25/2013
78 FR 17866
17866-17868 (3 pages)
https://www.federalregister.gov/d/2013-06748 https://www.federalregister.gov/d/2013-06748
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Start Printed Page 17867Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents through the Center for Veterinary Medicine's (CVM's) FOIA Electronic Reading Room at http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm.
In addition, FDA is amending the animal drug regulations to reflect changes of sponsorship for an NADA and ANADA, and a change of a sponsor's drug labeler code.
RMS Laboratories, Inc., 1903 East First St., Vidalia, GA 30474, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-210 for GENESIS (triamcinolone acetonide) Topical Spray to Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137. Following this change of sponsorship, RMS Laboratories, Inc., will no longer be the sponsor of an approved application.
Teva Animal Health, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-176 for PRAZITECH (praziquantel) Injectable Solution to Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.
Abbott Laboratories, North Chicago, IL 60064, has informed FDA of a change in drug labeler code. Accordingly, the Agency is amending the regulations in 21 CFR 510.600 to reflect this change of drug labeler code and to remove entries for RMS Laboratories, Inc., and in 21 CFR parts 522 and 529 to make conforming changes to Abbott Laboratories' product listings.
Table 1—Original and Supplemental NADAs and ANADAs Approved During January 2013
200-541 Parnell Technologies Pty. Ltd., unit 4, 476 Gardeners Rd., Alexandria, New South Wales 2015, Australia GONABREED (gonadorelin acetate) Injectable Solution 1. Original approval as a generic copy of NADA 098-379; and 2. Supplemental approval for use with cloprostenol sodium to synchronize estrous cycles to allow for fixed time artificial insemination in lactating dairy cows and beef cows.1 522.1073 yes 1. CE 2 2. EA/FONSI 3
1 Supplemental approval under section 512(b)(1) of the Federal Food, Drug, and Cosmetic Act.
2 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment.
3 Based on its review of an EA submitted by the sponsor, the Agency has concluded that this action will not have a significant impact on the human environment and that an EIS is not required. A finding of no significant impact (FONSI) has been prepared.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, 524, and 529 are amended as follows:
a. In the table in paragraph (c)(1), revise the entry for “Abbott Laboratories” and remove the entry for “RMS Laboratories, Inc.”; and
b. In the table in paragraph (c)(2), remove the entries for “000074” and “067292” and add an entry for “000044” in numerical order.
Abbott Laboratories, North Chicago, IL 60064 000044
000044 Abbott Laboratories, North Chicago, IL 60064.
4. Add § 522.1073 to read as follows:
§ 522.1073
(a) Specifications. Each milliliter of solution contains 100 micrograms (µg) of gonadorelin as gonadorelin acetate.
(b) Sponsor. See No. 068504 in § 510.600(c) of this chapter.Start Printed Page 17868
(c) Conditions of use in cattle— (1) Indications for use and amounts.
(i) For the treatment of ovarian follicular cysts in dairy cattle. Administer 100 µg gonadorelin by intramuscular or intravenous injection.
(ii) For use with cloprostenol sodium to synchronize estrous cycles to allow for fixed-time artificial insemination in lactating dairy cows and beef cows. Administer to each cow 100 µg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 µg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 µg gonadorelin by intramuscular injection.
5. In § 522.1077, revise the section heading to read as set forth below; and in paragraph (c)(3), remove the first sentence.
[Redesignated as § 522.1075]
6. Redesignate § 522.1078 as § 522.1075.
7. In § 522.1870, revise the section heading and paragraphs (b), (c)(1)(iii), and (c)(2)(iii) to read as follows:
(b) Sponsors. See Nos. 000859 and 061623 in § 510.600(c) of this chapter.
8. In paragraph (b)(2) of § 522.2005, remove “000074” and in its place add “000044”.
10. In paragraph (b) of § 524.2482, remove “067292” and in its place add “051311”.
12. In paragraph (b) of § 529.1186, remove “000074” and in its place add “000044”.
13. In paragraph (b) of § 529.2150, remove “000074” and in its place add “000044”.
[FR Doc. 2013-06748 Filed 3-22-13; 8:45 am]